CORRECTION

Correction to: Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology

Mark David Tricklebank[1] · Trevor W. Robbins[2] · Camilla Simmons[1] · Erik H. F. Wong[3]

Correction to: Psychopharmacology
https://doi.org/10.1007/s00213-021–05787-x

We wish to correct the attribution of the statement "substances capable of reducing neurotransmission at the NMDA receptor complex may represent a new class of antidepressant compounds (Krystal et al. 2019)". This statement was in fact made by Trullas and Skolnick (1990) on the basis of the behavioural response of mice to NMDA receptor antagonists to inescapable stress. Although Berman et al. (2000) performed the first human studies which ultimately led to the FDA approval of the use of ketamine for treatment resistant depression, they were aware of the Trullas and Skolnick work in animals, as is made clear in Krystal et al. (2019). We apologise for this accidental misattribution.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at https://doi.org/10.1007/s00213-021-05787-x

✉ Mark David Tricklebank
  tricklebank.mark@kcl.ac.uk

1   Centre for Neuroimaging Sciences, Institute of Psychiatry Psychology and Neuroscience, King's College, London, UK

2   Department of Psychology and Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge CB23EB, UK

3   Department of Psychiatry, University of British Columbia, Vancouver, Canada